COMP <GO>
GTBP vs ASBP // NET PROFIT MARGIN
GT Biopharma Inc. (NASDAQ) VS. Aspire-Lakewood Holdings Inc. (NASDAQ) • 15-METRIC TALLY: GTBP 2
— ASBP 2
■ METRIC PARITY
LAST: $5.60 (+1.63%) • MKT CAP: $11.5M
net-margins
—
LAST: $8.48 (-4.50%) • MKT CAP: $11.9M
net-margins
-60.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GTBP VS. ASBP)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | GTBP | ASBP | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | -1.90% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin ACTIVE | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 1.98% | 0.00% | +1.98 | GTBP | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 1/9 | +1.00 | GTBP | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 41.4 | 45.2 | -3.87 | ASBP | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $11.5M | $11.9M | -$351.8K | ASBP | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | GTBP REV | ASBP REV | GTBP GROSS % | ASBP GROSS % | GTBP FCF | ASBP FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $6.2K | — | -1.9% | -$12.9M | -$4.9M |
| FY 2024 | $0 | $0 | — | — | -$12.9M | -$265.2K |
| FY 2023 | $0 | $0 | — | — | -$8.9M | -$653.1K |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GTBP // BETA —
ASBP // BETA —